A Központ doktori kurzusait kizárólag angol nyelven oktatja. A doktori kurzusok a 2020/21 év őszi félévétől indulnak.
Course director: Prof. Zoltán Vokó
4-day course in biostatistics (2 credits)
Each day consists of 6 x 45-minute classes plus 10 hours self-study
Date: 20-23 January 2025, 9:00 AM – 4:00 PM
Location: Beznák Aladár Lecture Hall, Basic Medical Science Center, Semmelweis University
|
Day 1 |
Systematic literature review |
Zsuzsanna Petykó |
|
Day 2-4 |
Meta-analyses, Network meta-analyses |
Zoltán Vokó |
Technical requirements: participants should bring their own computer
Evaluation of prior PhD courses by participants and Action plan (in HU):
Course director: Prof. Zoltán Kaló
4-day course in pharmaceutical research and development (2 credits)
Each day consists of 7 x 45-minute classes
|
Day 1 |
Development of health economic model |
Balázs Nagy |
|
Day 2 |
Early phase economic modelling |
Zoltán Kaló |
|
Day 3 |
Strategic pricing of pharmaceutical technologies |
Zoltán Kaló |
|
Day 4 |
Net present value calculation to support development decisions |
Zoltán Kaló |
Technical requirements: participants should bring their own computer
Evaluation of prior PhD courses by participants and Action plan (in HU):
Course director: András Inotai
4-day course in health policy (2 credits)
Each day consists of 6 x 45-minute classes
|
Day 1 |
Principles of health economics, elements of health technology assessment, economic evaluations |
Zoltán Kaló/ András Inotai |
|
Day 2 |
Development of cost-effectiveness and budget impact models to support pharmaceutical policy decisions |
Balázs Nagy |
|
Day 3 |
Theory and practice of managed entry decisions |
András Inotai |
|
Day 4 |
Principles and implementation of value frameworks and Multicriteria Decision Analyses to support policy decisions |
Zoltán Kaló |
Technical requirements: participants should bring their own computer
For more information: https://semmelweis.hu/hta/oktatas/phd-kepzes/applied-health-economics/
Evaluation of prior PhD courses by participants and Action plan (in HU):
EVIDENCE-BASED PHARMACEUTICAL POLICY DECISION-MAKING IN LOWER-INCOME EUROPEAN COUNTRIES Evaluation